Filmed live at the JPMorgan Healthcare Conference 2026, this episode of the Making Medicine Podcast examines how global power shifts are reshaping the pharmaceutical industry. This Part 1 conversation features host John Stanford with former Senator Richard Burr and EU Commissioner Phil Hogan as they discuss whether the pharmaceutical industry is losing its long-held “geopolitical immunity.” As thousands of leaders gather in San Francisco for the year’s biggest healthcare event, the discussion offers a roadmap for navigating the shift from business as usual to a new era of geopolitical scrutiny.

What do you think is the biggest "opportunity in the chaos" for biotech in 2026?
Do you believe the FDA will become more or less predictable under the current administration?
How should global pharma companies prepare for the rise of "MAHA" and lifestyle-focused health policy?

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Timestamps
0:00 Welcome to Making Medicine
0:47 Meet the Panel: Senator Richard Burr & Commissioner Phil Hogan
2:21 2026 Outlook: The Disruptive Impact of the Second Trump Admin
3:51 Finding Opportunity in Policy Chaos
6:06 Why Pharma Lost Its "Geopolitical Immunity" in Trade
8:44 Most Favored Nation (MFN) and Global Pricing Realities
10:14 Defining "MAHA" and the Future of Health Policy
11:43 The Power of Direct Engagement: Bringing CEOs to the Hill
15:02 The FDA in 2026: Stability vs. Disruption
17:49 AI and Robotics: The New Subsectors of Medicine
19:08 China, Russia, and the Protection of the Single Market
25:15 2026 Predictions: Cultural Shifts and Economic Roller Coasters

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.